ED
ACTG icon

Exane Derivatives’s Acacia Research ACTG Stock Holding History

Exane Derivatives’s Portfolio ACTG Stock Details ACTG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,440
Closed -$81.6K – 1047
2021
Q2 		$81.6K Buy
+13,440
New +$80K 0.02% 571

Other funds holding ACTG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
PRCP
Pacific Ridge Capital Partners Lake Oswego, Oregon $462M AUM 40.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exane Derivatives's ACTG Position: Q3 2021 in Review

Exane Derivatives sold out of Acacia Research (ACTG) in Q3 2021, closing a stake of 13,440 shares — an estimated $81.6K sold.

Exane Derivatives first reported a position in ACTG in Q2 2021 and held it in 1 quarter. The position peaked at $81.6K in Q2 2021. 102 funds tracked by Wall St. Rank hold ACTG as of Q3 2021.

  • Exane Derivatives reported no remaining Acacia Research position as of Q3 2021 after selling out during the quarter.
  • Exane Derivatives sold 13,440 Acacia Research shares in Q3 2021, an estimated $81.6K.
  • Exane Derivatives first reported a position in Acacia Research in Q2 2021 and held it in 1 quarter.
  • Exane Derivatives's Acacia Research position peaked at $81.6K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Acacia Research as of Q3 2021.

Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.